Dataset Information

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

ABSTRACT:

Background

Prurigo nodularis (PN) is a poorly understood, understudied pruritic dermatosis that reduces quality of life.

Objective

To characterize the demographics and comorbidities associated with PN.

Methods

Cross-sectional study of patients 18 years and older who were seen at the Johns Hopkins Health System between December 6, 2012, and December 6, 2017.

Results

Over the past 5 years, 909 patients with PN were seen at Johns Hopkins Health System. African American patients were 3.4 times more likely to have PN than white patients were (odds ratio [OR], 3.4; 95% confidence interval [CI], 2.9-3.9; P < .001). A comparison of the study patients and race-matched controls revealed that PN was significantly associated with a variety of systemic, cardiovascular, and psychiatric comorbidities, including chronic kidney disease, chronic hepatitis C, chronic obstructive pulmonary disease, congestive heart failure, depression, and atopic dermatitis. Black patients with PN were 10.5 times more likely (OR, 10.5; 95% CI, 7.9-13.9; P < .001) to have HIV than were race-matched controls with atopic dermatitis, and 8 times more likely (OR, 8.0; 95% CI, 5.7-11.1; P < .001) to have HIV than were African American patients with psoriasis.

Limitations

Our data describe patients seen by 1 hospital system. Our data identify associated conditions and comorbidities but are unable to support a causal relationship.

Conclusion

PN disproportionately affects African Americans and is associated with several systemic conditions, including HIV, chronic kidney disease, and diabetes.

SUBMITTER: Boozalis E

PROVIDER: S-EPMC6518410 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

Boozalis Emily E Tang Olive O Patel Shivani S Semenov Yevgeniy R YR Pereira Manuel P MP Stander Sonja S Kang Sewon S Kwatra Shawn G SG

Journal of the American Academy of Dermatology 20180504 4

<h4>Background</h4>Prurigo nodularis (PN) is a poorly understood, understudied pruritic dermatosis that reduces quality of life.<h4>Objective</h4>To characterize the demographics and comorbidities associated with PN.<h4>Methods</h4>Cross-sectional study of patients 18 years and older who were seen at the Johns Hopkins Health System between December 6, 2012, and December 6, 2017.<h4>Results</h4>Over the past 5 years, 909 patients with PN were seen at Johns Hopkins Health System. African American ...[more]

PMID: 29733939

Similar Datasets

Project description:Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching. Patients with CPG experience a significant psychological burden and a notable impairment in their quality of life. Chronic prurigo of nodular type (CNPG; synonym: prurigo nodularis) represents the most common subtype of CPG. As CNPG is representative for all CPG subtypes, we refer in this review to both CNPG and CPG. We provide an overview of the clinical characteristics and assessment of CPG, the burden of disease and the underlying pathophysiology including associated therapeutic targets. The information provided results from a PubMed search for the latest publications and a database search for current clinical trials (ClinicalTrials.gov, EU Clinical Trials Register [European Medicines Agency]; using the following terms or combinations of terms: 'chronic prurigo', 'prurigo', 'prurigo nodularis', 'pathophysiology', 'therapy', 'biologics', 'treatment'). Dupilumab is the first authorized systemic therapy by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for CNPG to date. Topical and systemic agents that are currently under investigation in clinical randomized, placebo-controlled phase II and III trials such as biologics (e.g., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) and the opioid modulator nalbuphine are highlighted. In the last past 15 years, several milestones have been reached regarding the disease understanding of CPG such as first transcriptomic analysis, first terminology, first guideline, and first therapy approval in 2022, which contributed to improved medical care of affected patients. The broad range of identified targets, current case observations and initiated trials offers the possibility of more drug approvals in the near future.

Dataset Information

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

Background

Objective

Methods

Results

Limitations

Conclusion

Publications

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets